Stromal Vascular Fraction Market Expected to Reach US$ 102 Mn by 2025

Stromal Vascular Fraction Market Will Reach US$ 102 Mn by 2025
Prevalence of knee osteoarthritis is expected to provide a significant opportunity to the new class
cell therapies to penetrate the market. Moreover, soaring demand for reconstructive breast therapies
are also estimated to fuel the market in near future. Among all the clinical trials being conducted for
stromal vascular fraction therapeutics, breast reconstruction procedures have reported highest
proportion and outcomes for it to appear promising, as per the research conducted by Persistence
Market Research. Another opportunity lies in the therapy for scleroderma, as there has already been
an approved cell therapy that holds tremendous growth potential.
Persistence Market Research has recently published a research report on the global stromal vascular
fraction, titled “Stromal Vascular Fraction Market: Global Industry Analysis 2012 – 2016 and
Forecast 2017 – 2025.” The report indicates moderate growth for the SVF market during the
forecast period 2017-2025, at an estimated CAGR of 4.2%. From the global sales achieved in 2017,
i.e. US$ 73.14 Mn, the market is anticipated to attain a value worth US$ 101.92 Mn by the end of
2025.
Report overview @ https://www.persistencemarketresearch.com/market-research/stromal-vascularfraction-market.asp
Global Stromal Vascular Fraction Market: Dynamics : The growth of the global stromal vascular
fraction market is primarily driven by increasing adoption in applications such as skin treatment,
migraine and headaches, arthritis, diabetes, migraine, joint replacement and also in neurological
conditions such as amyotrophic lateral sclerosis (ALS), neuropathy, and Parkinson’s disease. In
addition, increasing prevalence and incidence of above-mentioned application are also gardening
the market growth of stromal vascular fraction market. For instance, according to the research
conducted, ALS affects more than 32,000 individuals and approximately 5,100 new cases diagnosed
each year in U.S. alone. However, factors such as high cost of treatment and complex regulatory
framework are the major obstacles in hampering the market growth of stromal vascular fraction.
Request Sample Report@ https://www.persistencemarketresearch.com/samples/20914
Global Stromal Vascular Fraction Market: Regional Analysis : North America’s SVF market is
expected to contribute more than 38% revenue share in the global market for stromal vascular
fraction over 2017-2025. Increasing number of IRB approvals for new SVF deployment procedures
developed by various research facilities and hospitals in the US is driving the demand for procedure
the North American market. As per the report published by Persistence Market Research, North
America will stay dominant throughout the forecast period, in terms of value. Asia Pacific, slated
for a relatively higher CAGR value over 2017-2025, will be reportedly followed by the European
market for SVF therapies. South Korea has been identified to be the fastest emerging, most
lucrative regional market for stromal vascular fraction, with over 5% CAGR during the assessment
period.
Request Report Multiple Chapter @ https://www.persistencemarketresearch.com/multiplechapter/20914
Global Stromal Vascular Fraction Market: Key Players : The report includes in-depth profiles of
some of the key players that are financialy active in the competitive landscape of the global stromal
vascular fraction market. Cytori Therapeutics Inc., IntelliCell BioSciences Inc. , Cellular
Biomedicine Group, Inc., GE Healthcare (Biosafe Group SA), Lifecell Corporation (Allergen PLC),
Tissue Genesis Inc., and InGeneron, Inc. are a few of the leading players in the global marketplace
for stromal vascular fraction.